There is a striking parallel between A2AR over-activation/over-expression and impaired GR receptor function, as evidenced by the similar ability of A2AR and GR antagonists to improve cognitive deficits as well as to mitigate amyloid and Tau pathologies reminiscent of AD14, 15, 16, 17. The gene discussed is NR3C1; the disease is Cognitive impairment.